Introduction
Endothelium-derived nitric oxide (NO) is a potent vasodilator. NO synthesized by endothelial NO synthase (eNOS) diffuses into the smooth muscle cells, and stimulates the soluble guanylate cyclase (sGC), leading to increased cGMP production and smooth muscle relaxation (Moncada and Higgs, 1993) . Several findings have suggested that excess superoxide (O 2 − ) produced in vascular cells interacts with NO, induces the abnormality of vascular tonus regulation and results in the development of hypertension (Jung et al., 2004; Rajagopalan et al., 1996) . In addition, Laursen et al. (1997) reported that both the development of hypertension and the altered endothelium-dependent vascular relaxation were improved by the treatment with membrane-targeted forms of superoxide dismutase in angiotensin II-induced hypertensive rats. Thus, it seems likely that the suppression of oxidative stress improves the NO bioavailability and prevents the development of hypertension and end organ damage (Schmieder, 2005; Zhou et al., 2003) .
Sesamin ( Figure 1 ) is one of the lignans found in high concentration in sesame seeds and oil. We have obtained evidence that dietary sesamin efficiently suppressed the development and maintenance of hypertension in deoxycorticosterone acetate (DOCA)-salt-induced hypertensive , two-kidney, one-clip renal hypertensive , and salt-loaded stroke-prone spontaneously hypertensive rats (Matsumura et al., 1998) , and that the suppressive effect of sesamin on DOCA-salt-induced hypertension was related to an inhibitory effect on the aortic O 2 − production of hypertensive animals (Nakano et al., 2003) . However, the mechanisms by which sesamin-feeding reduced the O 2 − production were not clear, because sesamin itself has little radical-scavenging ability in vitro. A previous study investigating the metabolic pathway of sesamin, given orally to rats, demonstrated that the JPET #100149 6 methylenedioxyphenyl moiety in the structure of sesamin was changed into a dihydroxyphenyl (catechol) moiety in the liver (Figure 1) , and that the metabolic products had potent radical-scavenging activities in vitro (Nakai et al., 2003) . Thus, we hypothesized that these radical-scavenging activities of sesamin metabolites would modulate the vascular tone and contribute to the antihypertensive effect induced by sesamin-feeding. Materials. Sesamin and its metabolites were prepared as described previously (Nakai et al., 2003) . To obtain sesamin metabolites, sesamin was orally administered to the rat, and bile was collected through a cannula placed into the biliary duct. The sesamin metabolites ( Figure 1 ) were obtained from this bile sample after being reacted with an enzyme mixture of glucuronidase and sulfatase. Sesamin-containing diets (1 w/w% in commercial normal diet, NMF) were obtained from Oriental Yeast Co., Ltd.
(Tokyo, Japan). N G -nitro-L-arginine (NOARG) and 7α,17β-[9[(4,4,5,5,5-pentafluoropentyl) 
Measurement of Aortic
The O 2 − production from xanthine/xanthine oxidase (X/XO) reaction was measured using a lucigenin-enhanced chemiluminescence assay (Nakano et al., 2003) . The lucigenin concentration was set to 5 µM, which demonstrated that its own redox cycling is minimal (Li et al., 1998; Skatchkov et al., 1999 and incubated with or without each sesamin metabolite (50 µM) or O 2 − scavenger 4,5-dihydroxy-1,3-benzene-disulfonic acid (tiron; 50 µM) in the dark condition for 15 min at 37℃, before measurement. Luminescence was measured using a luminometer (Sirius-2; Funakoshi, Tokyo, Japan). Background counts were determined from identically treated xanthine-free readings and subtracted from the X/XO readings.
X/XO-induced O 2 − production was expressed as relative light units (RLU) per min.
Isometric Tension Studies. The thoracic aortas from the male SD rats (body weight; 250-400 g) were removed, freed from fat and adherent connective tissue, and cut into strips taking special care to preserve the endothelium. In some strips, the endothelium was removed by gently rubbing the intimal surface with a cotton ball.
About 2-mm aortic segments of the thoracic aorta were suspended in organ chambers containing 10 ml of Krebs-Ringer bicarbonate solution (118.5 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 10 mM glucose) under a resting tension of 1.5 g at 37°C and gassed with 95% O 2 -5% CO 2 . Contractions and relaxations were measured as changes in isometric tension using a force displacement transducer (TB-612T, Nihon Kohden, Osaka, Japan) coupled to a polygraph (RM 6000, Nihon Kohden). After a 1.5-h equilibration period, vessels were contracted with 1 µM phenylephrine (Phe) and subsequently treated with 1 µM acetylcholine (Ach) to test the tissue viability. The endothelium was considered functional when the relaxation of precontracted vessels to 1 µM Ach was at least 90%. The endothelium removal was verified by the abolition or marked suppression of the Ach-induced relaxation, and by obtaining the strong relaxation (at least 90%) in response to the addition of 1 µM sodium nitroprusside. After a further equilibration period of more than 30 min was taken, the JPET #100149 9 vessels were precontracted with 1 µM Phe. After the precontraction reached a plateau, the relaxant response to vehicle or each sesamin metabolite (1, 10 and 50 µM; cumulative dosage) was evaluated. Thereafter, the same vessels were equilibrated over 30 min, and Binding assay. Competitive binding assays were performed as described previously (Sheen et al., 1985; Pruneau et al., 1998) . MCF-7 human breast cancer cells were used as the source of estrogen receptor and CHO cells were used as the source of bradykinin B 2 receptor. For the assay of estrogen receptor, the homogenate of cells was centrifuged (800 xg for 10 min), and the supernatant was collected. The clued nuclear pellet was washed twice at 4 °C with lysis buffer, and the nuclear washes were combined with the supernatant fraction. This was centrifuged at 180,000 xg for 30 min to yield the cytosol.
Aliquots of cytosol were incubated with Western blotting. The rat thoracic aortas were obtained as described above.
Aortas were immersed in test tubes containing modified Krebs-HEPES buffer (pH 7.4, 99.01 mM NaCl, 4.69 mM KCl, 1.87 mM CaCl 2 , 1.20 mM MgSO 4 , 1.03 mM K 2 HPO 4 , 25 mM Na-HEPES, 11.1 mM glucose) and incubated with piperitol (SC-1m) or demethylpiperitol (SC-1) (1, 10, or 50 µM) for 6 h at 37℃. Western blotting was performed as described previously (Yamashita et al., 2003) . Briefly, equal amounts of protein (30 µg) were fractionated using 7.5% SDS-polyacrylamide gels. After transfer to nitrocellulose membrane (Amersham Pharmacia Biotech, Arlington Heights, IL, U.S.A.), the blots were blocked for 60 min at 4 °C with 7.5% nonfat dry milk in TBS containing 0.1% Tween20. After blocking, the blots were incubated with anti-actin and anti-eNOS polyclonal antibody (BD Biosciences, San Jose, CA, U.S.A.) at 1:1000 dilution with 7.5% nonfat dry milk in TBS containing 0.1% Tween20 overnight at 4 °C.
After washing, the preparations were further incubated with goat anti-rabbit IgG Chronic NOS inhibition in rats. Experiments were performed on male SD rats (6 weeks old). For NO synthase inhibition, these rats were given drinking water containing NOARG at a concentration of 2.74 mM for 4 weeks. Intravenous bolus injection of NOS inhibitor (N G -nitro-L-arginine-methyl ester, L-NAME; 3 mg/kg) did not add to the hypertensive responses in these animals, suggesting that this dose of NOARG was adequate to block the influence of NOS on blood pressure regulation.
Animals were divided into three groups: i) vehicle-treated group; ii) NOARG + normal diet group; iii) NOARG + 1% sesamin-containing diet group. Treatment with the sesamin-containing diet was started at the beginning of NOARG treatment.
Normotensive control animals received distilled water as vehicle throughout the study.
Systolic blood pressure (SBP) was monitored using the tail cuff method and a pneumatic pulse transducer (BP-98A, Softron, Tokyo, Japan).
Deoxycorticosterone acetate (DOCA)-salt treatment in eNOS-deficient mice.
C57bl/6J wild-type and eNOS −/− mice (6 weeks old) were anesthetized with sodium pentobarbital (40 mg/kg, i.p.), and the right kidney was removed via a right flank incision. After a 1-week postsurgical recovery period, the mice were separated into a sham-operated group, DOCA-salt normal diet group and DOCA-salt sesamin containing diet-fed group. The sham-operated groups were given tap water and normal diet ad libitum. Mice in the DOCA-salt group were treated three times weekly with DOCA suspended in corn oil, which was administered subcutaneously (75 mg/kg), and 1%
NaCl was added to their tap water for drinking. Treatment with the sesamin-containing diet was started at the beginning of DOCA-salt treatment.
Measurement of plasma concentrations of sesamin and sesamin metabolites.
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Sprague Dawly rats were fed the 1% sesamin-containing diet for 4 weeks. The blood was drawn from the abdominal aorta and was centrifuged to obtain the plasma. Figure   3C represents the maximal vasorelaxation response induced by 50 µM of each sesamin metabolite or tiron. Vasorelaxations induced by SC-1m, SC-1 and SC-2m were markedly attenuated by endothelium removal, although 10-20% relaxation was seen in endothelium-denuded vessels (50 µM: 20.4 ± 3.6%, 20.6 ± 6.6%, and 9.2 ± 3.0%, respectively).
Results

Effects
Effects of NOARG and ODQ on SC-1m-or SC-1-induced vasorelaxation. To investigate the mechanisms of the sesamin metabolites-induced endothelium-dependent JPET #100149 14 vasorelaxation, the possible involvement of the NOS-NO-sGC system was evaluated.
Both SC-1m-and SC-1-induced relaxations were significantly inhibited by pretreatment with NOARG (50 µM SC-1m, 18.3 ± 4.7%; 50 µM SC-1, 21.3 ± 4.3%) or ODQ (50 µM SC-1m, 18.1 ± 3.6%; 50 µM SC-1, 19.2 ± 1.3%) (Figure 4 ). On the other hand, both the SC-1m-and SC-1-induced relaxations were unaltered by pretreatment with atropine, propranolol, ICI 182,780, pyrilamine, reactive blue 2, or wortmannin (Table 1) . receptor (data not shown).
Effects of sesamin metabolites on aortic eNOS protein. The possibility that
sesamin metabolites regulate the expression of eNOS protein was evaluated. Western blot analysis for eNOS was performed on the isolated rat aortas incubated with vehicle, SC-1m or SC-1 for 6 h, and revealed no differences in the relative levels of eNOS expression between the vehicle-and sesamin metabolite-treated vessels ( Figure 5 ).
Effects of the sesamin feeding on NOS inhibitor-induced hypertension in rats.
The blood pressure of NOARG-treated animals markedly increased at day 2 of the experimental period (Figure 6 ), and the elevated SBP was sustained at a high level throughout the 4 weeks (SBP; baseline: 107.1 ± 1.9 mmHg, at 4 weeks: 146.3 ± 2.7 mmHg). Changes of SBP of NOARG-treated sesamin-fed rats (SBP; baseline:
107.47 ± 1.33 mmHg, at 4 weeks: 143.51 ± 2.85 mmHg) were almost identical to those of normal diet-fed hypertensive control rats.
Effects of sesamin feeding on DOCA-salt-induced hypertension in eNOS
In wild-type mice, DOCA-salt treatment for 5 weeks significantly increased the blood mice, the DOCA-salt-induced increase in blood pressure (SBP; baseline: 124.7 ± 1.8 mmHg, at 5 weeks: 150.7 ± 5.5 mmHg) was not affected by 5 weeks of sesamin feeding (SBP; baseline: 124.5 ± 1.1 mmHg, at 5 weeks: 147.1 ± 2.7 mmHg) (Figure 7b ).
Plasma concentrations of sesamin and sesamin metabolites. Plasma
concentrations of sesamin metabolites after sesamin feeding to rats are shown in Table 2 .
After 4-weeks feeding of 1% sesamin-containing diet, each sesamin metabolite was detected in rat plasma at concentrations over 1 µM, and SC-1 was a major metabolite in the plasma.
Discussion
We previously reported that chronic sesamin-feeding effectively suppressed the DOCA-salt-induced hypertension and the enhancement of aortic O 2 − production, whereas a combination of classical antihypertensive drugs (reserpine, hydralazine and thiazide) failed to decrease the O 2 − production despite the fact that the blood-pressure lowering effect was more potent than in the case of sesamin-feeding (Nakano et al., 2003) . Thus, we suggested that the antioxidative activity of sesamin-feeding contributes to its antihypertensive action. However, the mechanisms by which sesamin feeding reduced the O 2 − production were not clear, because sesamin itself has little radical-scavenging ability in vitro (Nakai et al., 2003) . A previous study (Nakai et al., 2003) demonstrated that several metabolites, which have a mono-or di-catechol moiety in their structures and exhibit strong radical scavenging activities, were found in the bile after the oral administration of sesamin. We also observed the radical scavenging activities of sesamin metabolites, especially SC-1, SC-2m and SC-2. These findings led us to hypothesize that the radical scavenging activity of sesamin metabolites may modulate vascular tone by improving NO bioavailability. However, a potent NO-dependent vasorelaxation was observed in aorta treated with SC-1m, which has little antioxidative activity, and there was no correlation between the antioxidative activity and the vasorelaxing activity of each sesamin metabolite. Thus, it seems likely that sesamin metabolites induce the NO-dependent vascular relaxation irrespective of their antioxidant activity.
In our previous study (Nakano et al., 2003) , sesamin-feeding and tempol (an SOD mimetic) treatment significantly suppressed the enhancement of vascular O 2 − production in DOCA-salt-treated rats, to the same extent. However, the degree of the suppressing effect on blood pressure elevation was greater in the sesamin fed-rats than in the tempol-treated rats, indicating that the antihypertensive effect of sesamin-feeding was not only due to the antioxidative effect, but also due to the other unknown mechanisms. One of these unknown mechanisms may be closely related to the sesamin metabolites-induced NO-dependent vasorelaxing effect, which is independent of their antioxidative properties. The findings that the sesamin feeding-induced
antihypertensive effect was not observed in chronically NOARG-treated rats or in DOCA-salt-treated eNOS −/− mice, supported this possibility.
The precise upstream mechanism by which sesamin metabolites stimulate NOS-NO-sGC signaling was not clear. Some flavonoids derived from natural compounds, such as genistein, daidzein and apigenin, have been shown to compete with 17β-estradiol for binding to the estrogen receptor, acting as phytoestrogens (Kuiper et al., 1998) . Thus, the vasorelaxant activities of SC-1m and SC-1 may be the result of the activation of the estrogen receptor, which is known to induce the enhancement of the eNOS activity via the activation of the PI3K/Akt signaling cascade (Chambliss et al., 2000; Simoncini et al., 2003) and the NO-mediated vasorelaxation (Bolego et al., 2005) .
Therefore, we examined whether SC-1m and SC-1 also compete with 17β-estradiol for binding to the estrogen receptor. In fact, SC-1 had some affinities to the estrogen receptor. However, the concentration of SC-1 required to compete with 17β-estradiol was 10,000 higher than that of 17β-estradiol (IC50; SC-1: 11.0 µM, 17β-estradiol: 1.1 nM). Furthermore, preincubation with ICI 182,780 and wortmannin did not modify the relaxant responses to SC-1m and SC-1. Taken together, it is unlikely that the sesamin metabolites act as phytoestrogen, at least in their vasorelaxant effects.
NOS in the endothelium is activated by signals through many G protein-coupled receptors, such as the muscarine M 3 (Lamping et al., 2004) , bradykinin B 2 (Leeb-Lundberg et al., 2005) , β-adrenergic (Ferro et al., 2004) , histamine H 1 (Hill et al., JPET #100149 18 1997) and purine P2Y (Ralevic and Burnstock, 1998) receptors. In the present study, pretreatment with atropine, propranolol, pyrilamine or reactive blue 2 did not modify the vasodilator effect of SC-1m or SC-1. Moreover, we observed that there is no competition between bradykinin and sesamin metabolites for binding to the bradykinin B 2 receptor. Thus, signaling systems through the muscarinic M 3 receptor, β-adrenergic receptor, estrogen receptor, histamine H 1 receptor, purine P2Y receptor and bradykinin B 2 receptor were not involved in the upstream mechanisms of SC-1m-and SC-1-induced NO-dependent vasorelaxation. There are many other mechanisms in regulating eNOS activity, such as increasing intracellular Ca 2+ level including the receptor-mediated Ca 2+ influx, protein phosphorylation (Michell et al., 2002) , intracellular translocation (Goetz et al., 1999) and association with other proteins (e.g. Sesamin metabolites produced slight vasorelaxations (10-20%) in endothelium-denuded aortas, suggesting that sesamin metabolites act directly on the smooth muscle cells to induce vasorelaxation. One potential mechanism is that sesamin metabolites may activate the neuronal NOS in smooth muscle cells. However, sesamin metabolites-induced vasorelaxations in endothelium-denuded aortas were similar to those in NOARG-treated aortas. Thus, it is difficult to consider that neuronal NOS contributes to the sesamin metabolites-induced endothelium-independent vasorelaxation. The other mechanisms, which are related to the smooth muscle relaxation, such as inhibition of Ca 2+ influx, inhibition of phosphodiesterase or opening K + channel, may contribute to these endothelium-independent vasorelaxations.
In the present experimental condition, SC-1, SC-2m and SC-2 exhibited similarly potent radical-scavenging properties against the X/XO-induced O 2 − production, suggesting that the radical-scavenging properties of these sesamin metabolites were largely attributable to the catechol moiety in their structures. However, the catechol moiety is not critical for the vasorelaxant activity of sesamin metabolites, since the presence of the catechol moiety does not correlate to the vasorelaxant potencies of sesamin metabolites. Rather, one of the important determinants for this activity may be the presence of the methylenedioxyphenyl moiety, which is contained in SC-1m and SC-1.
The sesamin-feeding-induced antioxidative effect contributed to the lowering of blood-pressure in DOCA-salt hypertensive rats (Nakano et al., 2003) . Therefore, we expected that sesamin-feeding would produce some antihypertensive effects in NOS-nonfunctional models via antioxidative mechanisms, even though the sesamin metabolites-induced NO-dependent vasorelaxant activity is an important mechanism of the sesamin-induced antihypertensive effect. However, sesamin-feeding failed to suppress the blood pressure elevation in NOARG-treated rats and DOCA-salt-treated
Recent studies demonstrated that tempol treatment had no effect on the blood pressure elevation in L-NAME-treated rats (Preti et al., 2005; Yanes et al., 2005) , and that DOCA-salt treatment did not increase the O 2 − production in the aortas of eNOS −/− mice (Landmesser et al., 2003) . We also noted that tempol treatment had no effect on the NOARG-induced hypertension, and that the aortic O 2 − production in NOARG-treated rats was not increased compared with that in normotensive rats (unpublished observations). Collectively, these results indicate that oxidative stress was not important, at least with regard to the blood pressure elevation of these hypertensive models. Thus, it is reasonable to consider that sesamin-feeding cannot JPET #100149 20 exhibit the antioxidative property-dependent antihypertensive effect, in NOS-nonfunctional models.
In the present study, we showed that sesamin metabolites were detected in rat plasma at concentrations over 1 µM, after 4-weeks feeding of 1% sesamin-containing diet. In particular, the plasma concentration of SC-1 was higher than those of other metabolites, and reached over 10 µM, which is able to induce the vasorelaxation in rat aortic ring. Thus, it is reasonable to consider that sesamin metabolites including SC-1 contribute to the systemic effect of sesamin-feeding.
In summary, sesamin metabolites, especially SC-1 and SC-1m, elicit endothelium-, JPET #100149 29   TABLE 2 Plasma concentrations of sesamin and sesamin metabolites in 1% sesamin-containing diet-fed rats.
SC-1m SC-1 SC-2m SC-2 sesamin µM 1.1 ± 0.2 12.7 ± 0.9 1.1 ± 0. 
